3759 Stock Overview
Provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 3759 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.00 |
| 52 Week High | CN¥24.85 |
| 52 Week Low | CN¥7.98 |
| Beta | 0.84 |
| 1 Month Change | -11.32% |
| 3 Month Change | -18.95% |
| 1 Year Change | -6.88% |
| 3 Year Change | -74.74% |
| 5 Year Change | n/a |
| Change since IPO | -81.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3759 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -7.8% | -7.0% | -3.5% |
| 1Y | -6.9% | -32.0% | 17.5% |
Return vs Industry: 3759 exceeded the Hong Kong Life Sciences industry which returned -30.4% over the past year.
Return vs Market: 3759 underperformed the Hong Kong Market which returned 18.5% over the past year.
Price Volatility
| 3759 volatility | |
|---|---|
| 3759 Average Weekly Movement | 10.8% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 3759 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3759's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 20,342 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
| 3759 fundamental statistics | |
|---|---|
| Market cap | HK$42.72b |
| Earnings (TTM) | HK$2.00b |
| Revenue (TTM) | HK$12.52b |
23.4x
P/E Ratio3.7x
P/S RatioIs 3759 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3759 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.80b |
| Cost of Revenue | CN¥7.77b |
| Gross Profit | CN¥4.02b |
| Other Expenses | CN¥2.14b |
| Earnings | CN¥1.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 1.06 |
| Gross Margin | 34.12% |
| Net Profit Margin | 15.97% |
| Debt/Equity Ratio | 38.7% |
How did 3759 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 07:16 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmaron Beijing Co., Ltd. is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Linda Lu | BOCI Research Ltd. |
| Yang Luo | BOCI Research Ltd. |
| Bo Li | BofA Global Research |